Stockscreener 앱 받기
0.25
18.27%
-0.0559
시간 외 거래:
.25
Nkgen Biotech Inc 주식(NKGN)의 최신 뉴스
NKGen Biotech Partners with HekaBio for SNK01 in Japan - TipRanks
NKGen and HekaBio partner to advance NK cell therapy in Japan By Investing.com - Investing.com South Africa
NKGen Biotech and HekaBio Enter Strategic Partnership to Bring Novel NK Cell Therapy to Japan - GlobeNewswire
Revolutionary NK Cell Therapy Targets Alzheimer's: NKGen Secures Fast-Track Access to Japanese Market - Stock Titan
NKGen Biotech Announces New Funding to Regain Compliance with Reporting Obligations and Listing Standards - GlobeNewswire
NKGen Biotech (NYSE:NKGN) versus CEL-SCI (NYSE:CVM) Head-To-Head Comparison - Defense World
Nasdaq Announces Delisting of Multiple Companies Including NKGen Biotech, Aquaron Acquisition Corp, and Others - Nasdaq
Delisting of Securities from The Nasdaq Stock Market - Yahoo Finance
NKGen Biotech (NYSE:NKGN) Stock Price Down 0.2% – What’s Next? - Defense World
NKGen administers first dose of NK cell therapy to Alzheimer’s patient By Investing.com - Investing.com South Africa
NKGen administers first dose of NK cell therapy to Alzheimer’s patient - Investing.com
NKGen Biotech Administers First Dose of Troculeucel to - GlobeNewswire
Breakthrough: New NK Cell Treatment Offers Hope for Alzheimer's Patients Who Failed Standard Therapy - Stock Titan
Revolutionary NK Cell Therapy for Alzheimer's Expands Clinical Trial to International Sites - Stock Titan
NKGNW SEC FilingsNKGen Biotech 10-K, 10-Q, 8-K Forms - Stock Titan
Nkgen biotech sees $2.5 million stock purchase by major shareholder - Investing.com Canada
NKGen Biotech Enters Stock Purchase Agreement - TipRanks
NKGen Biotech Delays Quarterly Report Filing - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally - GlobeNewswire
NKGen Biotech’s Strategic Stock Purchase Agreement - TipRanks
NKGen Biotech Chairman & CEO Paul Y. Song, M.D., Personally Invests $2.65 Million Cash to Accelerate Phase 2 Clinical Trial and Fulfill Financial Reporting Obligations - Stock Titan
NKGen Biotech to Present Phase 1 Clinical Data on Troculeucel for Alzheimer's Disease at ASGCT Annual Meeting - Nasdaq
NKGen Biotech to Present Troculeucel Clinical and Biomarker - GlobeNewswire
NKGen Biotech to Present Troculeucel Clinical and Biomarker Results at the American Society of Gene and Cell Therapy (ASGCT) 28th Annual Meeting - Stock Titan
Head-To-Head Review: NKGen Biotech (NYSE:NKGN) and Athira Pharma (NASDAQ:ATHA) - Defense World
NKGen Biotech secures amended loan terms with East West Bank By Investing.com - Investing.com India
NKGen Biotech secures amended loan terms with East West Bank - Investing.com
NKGen Biotech (NYSE:NKGN) Trading Up 4.3% – Here’s What Happened - Defense World
NKGen Biotech To Present on the Use of Troculeucel for - GlobeNewswire
Breakthrough NK Cell Therapy Data Reveals New Hope for Alzheimer's Patients - Stock Titan
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial - GlobeNewswire
NKGen Biotech Presents Data from Phase 1/2a Clinical Trial of Troculeucel in Moderate Alzheimer’s Disease at the International Conference on Alzheimer’s and Parkinson’s Diseases (AD/PD™ 2025) - Yahoo
Breakthrough: NK Cell Therapy Reverses Moderate Alzheimer's to Mild in Clinical Trial - Stock Titan
NKGen Biotech Delays Annual Report Filing - TipRanks
3 Stocks Near 52-Week Lows With Strong Rebound Potential - The Globe and Mail
NKGen Biotech to Present Phase 1 Results on Troculeucel NK Cell Therapy for Alzheimer's at AD/PD™ 2025 Conference - Nasdaq
NKGen Biotech To Present Updated Troculeucel Data at the - GlobeNewswire
Groundbreaking NK Cell Therapy Data for Alzheimer's: 6-Month Results to be Revealed at Major Conference - Stock Titan
Biotech Alert: Searches spiking for these stocks today - Yahoo Finance
NKGen Biotech To Present on Potential of Troculeucel for - GlobeNewswire
NKGen Biotech to Present Troculeucel as Potential Neurodegenerative Disease Therapy at Alzheimer’s & Parkinson’s Drug Development Summit - Nasdaq
NKGen Biotech To Present on Potential of Troculeucel for the Treatment of Neurodegenerative Diseases at the 13th Annual Alzheimer’s & Parkinson’s Drug Development Summit - GlobeNewswire
Revolutionary NK Cell Therapy Advances Against Alzheimer's: FDA Fast-Tracks Promising Treatment - StockTitan
NKGen Biotech secures $5 million convertible loan By Investing.com - Investing.com South Africa
NKGen Biotech secures $5 million convertible loan - Investing.com India
4 Biotech Stocks To Watch: CVM, NKGN, NBIO, IMUX - DRP Journal
NKGen Biotech moving to OTC Markets, cancels 1-for-6 reverse stock split - TipRanks
NKGen Biotech shifts to OTC Markets after Nasdaq delisting By Investing.com - Investing.com South Africa
NKGen Biotech shifts to OTC Markets after Nasdaq delisting - Investing.com India
NKGen Biotech, Inc. to Transition from the Nasdaq Global - GlobeNewswire
NKGen Biotech Delisted: What Happens to Its FDA Fast-Tracked Alzheimer's Program Now? - StockTitan
NKGen Biotech, Inc. SEC 10-Q Report - TradingView
0.64%
0.37%
자본화:
|
볼륨(24시간):